Predominantly antibody deficiency and the association with celiac disease in Sweden: A nationwide case-control study
- PMID: 38331244
- DOI: 10.1016/j.anai.2024.01.019
Predominantly antibody deficiency and the association with celiac disease in Sweden: A nationwide case-control study
Abstract
Background: Predominantly antibody deficiency (PAD) is associated with noninfectious inflammatory gastrointestinal disease. Population estimates of celiac disease (CeD) risk in those with PAD are limited.
Objective: To estimate population risk of PAD in individuals with CeD.
Methods: We conducted a nationwide case-control study in Swedish individuals who received a diagnosis of CeD between 1997 and 2017 (n = 34,980), matched to population comparators by age, sex, calendar year, and county. The CeD was confirmed through the Epidemiology Strengthened by histopathology Reports in Sweden study, which provided information on biopsy specimens from each of Sweden's pathology departments. PAD was identified using International Classification of Diseases, 10th Revision coding and categorized according to the International Union of Immunologic Societies. Logistic regression was used to calculate adjusted odds ratios (aORs) and 95% CIs.
Results: PAD was more prevalent in CeD than in population controls (n = 105 [0.3%] vs n = 57 [0.033%], respectively). This translated to an aOR of 8.23 (95% CI 5.95-11.48). The association was strongest with common variable immunodeficiency (aOR 17.25; 95% CI 6.86-52.40), and slightly lower in other PAD (aOR 8.39; 95% CI 5.79-12.32). The risk of CeD remained increased at least 5 years after diagnosis of PAD (aOR 4.79; 95% CI 2.89-7.97, P-heterogeneity ≤ 0.001).
Conclusion: PAD was associated with an increased risk of CeD. A particularly strong association was seen in those with CVID, although this should be interpreted cautiously given the limited understanding of the mechanisms of histopathologic changes in these patients.
Copyright © 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures Dr Khalili receives consulting fees from Takeda and grant funding from Takeda and Pfizer. Dr Ludvigsson has coordinated an effort on behalf of the Swedish Inflammatory Bowel Disease Quality Register that received funding from Janssen corporation and has received support from MSD/Merck for a manuscript reviewing national healthcare registers in China. Dr Farmer has received support from Pharming, Bristol-Myers Squibb, and Pfizer. Dr DiGiacomo has recieved support from Pfizer. These relationships have no direct relation to this work. Dr Roelstrate, Dr Green, Dr Lebwohl, and Dr Hammarstrom have no conflicts of interest to report.
Comment in
-
The shifting paradigm of gastrointestinal disease associated with antibody deficiencies.Ann Allergy Asthma Immunol. 2024 Jun;132(6):669-670. doi: 10.1016/j.anai.2024.03.007. Ann Allergy Asthma Immunol. 2024. PMID: 38839140 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical